GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: Is one approach more successful or preferable than the other?

International Journal of Clinical Practice

Volumn 68, Issue 5, 2014, Pages 557-567

  Brunton, S ^a  

^a Primary Care Metabolic Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT SATISFACTION; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84898964381     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12361     Document Type: Review

References (85)

1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control 2009. Endocr Pract 2009; 15: 540-59.
2. Davidson MH,. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011; 108 (3 Suppl.): 33B-41B.
3. Jose T, Inzucchi SE,. Cardiovascular effects of the DPP-4 inhibitors. Diabetes Vasc Dis Res 2012; 9: 109-16.
4. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-8.
5. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
6. Lovshin JA, Drucker DJ,. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
7. Hare KJ, Vilsbøll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2012; 59: 1765-70.
8. Vilsbøll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-9.
9. Mentis N, Vardarli I, Köthe LD, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011; 60: 1270-6.
10. Mentlein R, Gallwitz B, Schmidt WE,. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35.
11. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamiceffects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876-86.
12. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-88.
13. Drucker DJ,. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
14. Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010; 164: 58-64.
15. DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 1145-54.
16. Sanofi-aventis. Lixisenatide SPC: Lixisenatide summary of product characteristics. http://ec.europa.eu/health/documents/community-register/2013/ 20130201125120/anx-125120-en.pdf (accessed May 2013).
17. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-9.
18. Amylin Pharmaceuticals. Byetta SPC. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000698/WC500051845.pdf (accessed May 2013).
19. Novo Nordisk. Victoza SPC. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000698/WC500051845.pdf (accessed July 2012).
20. Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007; 78: 254-8.
21. Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009; 19: 45-53.
22. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407.
23. Gerich J,. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2012; 90: 131-40.
24. Davidson J,. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009; 76 (Suppl. 5): S28-S38.
25. Madsbad S,. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009; 23: 463-77.
26. Rosenstock J, Raccah D, Korányi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; 36: 2945-51.
27. Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013; 15: 1000-7.
28. Ahrén B, Leguizamo Dimas A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013; 36: 2543-50.
29. Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) (Abstract D-0743). Proceedings of the World Diabetes Congress 2011; December 4-8, 2011; Dubai, United Arab Emirates.
30. Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on met- formin (GetGoal-F1) [Abstract]. Diabetologia 2011; 54 (Suppl. 1): S316-S317.
31. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
32. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011; 54 (Suppl. 1): S38 (Abstract A75).
33. Stonehouse A, Walsh B, Cuddihy R,. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. Diabetes Technol Ther 2011; 13: 1063-9.
34. Holst JJ,. Pharmacology of GLP-1-based therapies. Br J Diab Vasc Dis 2008; 8: S11-S18.
35. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
36. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
37. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2006; 26: 268-78.
38. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-43.
39. Yabe D, Seino Y,. Liraglutide in adults with type 2 diabetes: global presepctive on safety, efficacy and patient preference. Clin Med Insights Endocrinol Diabetes 2011; 4: 47-62.
40. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.
41. Reid T,. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes 2012; 30: 3-12.
42. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-52.
43. Berg JK, Shenouda SK, Heilmann CR, et al. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011; 13: 982-9.
44. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-9.
45. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011; 28: 705-14.
46. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-56.
47. Davies M, Pratley R, Montanya E, et al. Liraglutide reduces A1c to a greater extent than sitagliptin regardless of baseline A1c levels. Diabetes 2010; 59 (Suppl. 1): A15 (Abstract 57-OR).
48. Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012; 35: 1986-93.
49. King AB, Montanya E, Pratley R, et al. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. Endocr Pract 2013; 19: 64-72.
50. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
51. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract 2013; 19: 327-36.
52. National Institute for Health and Clinical Excellence. (2009) Clinical guideline 87, the management of type 2 diabetes. http://www.nice.org.uk/ nicemedia/live/12165/44320/44320.pdf (accessed May 2013).
53. National Institute for Health and Clinical Excellence (2010) Final appraisal determination: Liraglutide for the treatment of type 2 diabetes mellitus. http://www.nice.org.uk/nicemedia/live/11895/50663/50663.pdf (accessed May 2013).
54. Novo Nordisk. Victoza PI. http://www.novo-pi.com/victoza.pdf (accessed May 2013).
55. Amylin Pharmaceuticals. Bydureon PI. http://documents.bydureon.com/ Bydureon-PI.pdf (accessed May 2013).
56. Amylin Pharmaceuticals. Bydureon SPC. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002020/WC500108241.pdf (accessed May 2013).
57. Amylin Pharmaceuticals. Byetta PI. http://documents.byetta.com/Byetta-PI. pdf (accessed May 2013).
58. Merck Sharp & Dohme Corp. Januvia PI. http://www.merck.com/product/ usa/pi-circulars/j/januvia/januvia-pi.pdf (accessed May 2013).
59. Merck Sharp & Dohme Corp. Januvia SPC. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000722/WC500039054.pdf (accessed May 2013).
60. Bristol-Myers Squibb. Onglyza SPC. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/001039/WC500044316.pdf (accessed May 2013).
61. Bristol-Myers Squibb. Onglyza PI. http://packageinserts.bms.com/pi/pi- onglyza.pdf (accessed May 2013).
62. Novartis. Galvus SPC. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000771/WC500020327.pdf (accessed May 2013).
63. Boehringer Ingelheim Pharmaceuticals, Inc. Trajenta SPC. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002110/WC500115745.pdf (accessed May 2013).
64. Boehringer Ingelheim Pharmaceuticals, Inc. Trajenta PI. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf (accessed May 2013).
65. Nakatani K, Kurose T, Hyo T, et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther 2012; 3: 14.
66. Nauck MA,. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-32.
67. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Diabetes Care 2009; 32: 834-8.
68. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-604.
69. Kahn SE,. Incretin therapy and islet pathology: a time for caution. Diabetes 2013; 62: 2178-80.
70. Food and Drug Administration. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm (accessed May 2013).
71. European Medicines Agency (EMA). Investigation into GLP-1-based diabetes therapies concluded. Press Release 26 July 2013. http://www.ema.europa.eu/docs/ en-GB/document-library/Press-release/2013/07/WC500146619.pdf (accessed September 2013).
72. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary in patients in type 2 diabetes. N Engl J Med 2013; 369: 1327-35.
73. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
74. López-Ruiz A, del Peso-Gilsanz C, Meoro-Avilés A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 2010; 32: 559-61.
75. Kaakeh Y, Kanjee S, Boone K, et al. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012; 32: e7-11.
76. Nandakoban H, Furlong TJ, Flack JR,. Acute tubulointerstitial nephritis following treatment with exenatide. Diabet Med 2013; 30: 123-5.
77. Weise WJ, Sivanandy MS, Block CA, et al. Exenatide-associated ischemic renal failure. Diabetes Care 2009; 32: e22-e23.
78. Kuehn B,. Exenatide and kidney function. JAMA 2009; 302: 2644.
79. Leibovitz E, Gottlieb S, Goldenberg I, et al. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol 2013; 12: 53.
80. Lean ME, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990; 7: 228-33.
81. Aucott LS,. Influences of weight loss on long-term diabetes outcomes. Proc Nutr Soc 2008; 67: 54-9.
82. Fujioka K,. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 186-94.
83. Ussher JR, Drucker DJ,. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
84. Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 2011; 34: 314-9.
85. Davies M, Pratley R, Hammer M, et al. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared to sitagliptin, each as add-on to metformin. Diabet Med 2011; 28: 333-7.